Intravenous Brincidofovir Effectively Reduces CMV Dnaemia In Antiviral Experienced Immunocompromised Patients: Results of a Phase 2a Clinical Trial (TCT-ASTCT-CIBMTR 2026) - Feb 6, 2026 - Abstract #LBA-4; 907; Pres time: Feb 7, 2026; 04:00 PM - 04:15 PM; Location: Ballroom AB (Salt Palace Convention Center); P2 | "Most patients (7/9 per Cohort) had failed ≥1 prior CMV antiviral (n=12 GCV or valGCV, 4 foscarnet, 4 letermovir, and 2 maribavir). IV BCV was effective in reducing CMV DNAemia and was reasonably well tolerated in this population of pre-treated immunocompromised patients. IV BCV is a potential treatment for patients with limited options. These data support further study of IV BCV for treatment of CMV infections."
Clinical • Late-breaking abstract • P2a data • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease
|
|
Fareed Khawaja; Genovefa Papanicolaou; Michael Grimley; Carlos Gomez; Kris Mahadeo; Caitlin Elgarten; Gabriela Marón; Randall Lanier; Ingrid Nielsen-Orzeck; Rochelle Maher; Nkechi Azie; Roy Chemaly
|